These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [How does the landscape change in lysosomal storage disease]. Parini R Pediatr Med Chir; 2007; 29(5):275-8. PubMed ID: 18402399 [No Abstract] [Full Text] [Related]
9. The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease. Hollak CE; Weinreb NJ Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):205-18. PubMed ID: 25987174 [TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy for lysosomal storage disorders: successful transition from concept to clinical practice. Sly WS Mo Med; 2004; 101(2):100-4. PubMed ID: 15119106 [TBL] [Abstract][Full Text] [Related]
12. Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases. Ivanova MM; Changsila E; Iaonou C; Goker-Alpan O PLoS One; 2019; 14(1):e0210617. PubMed ID: 30633777 [TBL] [Abstract][Full Text] [Related]
13. Newborn screening for lysosomal storage disorders. Nakamura K; Hattori K; Endo F Am J Med Genet C Semin Med Genet; 2011 Feb; 157C(1):63-71. PubMed ID: 21312327 [TBL] [Abstract][Full Text] [Related]
14. The role of antibodies in enzyme treatments and therapeutic strategies. Bigger BW; Saif M; Linthorst GE Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):183-94. PubMed ID: 25987172 [TBL] [Abstract][Full Text] [Related]
15. Gene therapy for the lysosomal storage disorders. Cabrera-Salazar MA; Novelli E; Barranger JA Curr Opin Mol Ther; 2002 Aug; 4(4):349-58. PubMed ID: 12222873 [TBL] [Abstract][Full Text] [Related]
16. [Lysosomal storage diseases]. Manger B Z Rheumatol; 2010 Aug; 69(6):527-38. PubMed ID: 20532791 [TBL] [Abstract][Full Text] [Related]
17. Chemical chaperones--a new concept in drug research. Kolter T; Wendeler M Chembiochem; 2003 Apr; 4(4):260-4. PubMed ID: 12672104 [No Abstract] [Full Text] [Related]
18. Enzyme replacement therapy: conception, chaos and culmination. Brady RO Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):915-9. PubMed ID: 12803925 [TBL] [Abstract][Full Text] [Related]
19. Pulmonary involvement in selected lysosomal storage diseases and the impact of enzyme replacement therapy: A state-of-the art review. Jezela-Stanek A; Chorostowska-Wynimko J; Tylki-Szymańska A Clin Respir J; 2020 May; 14(5):422-429. PubMed ID: 31912638 [TBL] [Abstract][Full Text] [Related]
20. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases. Sánchez-Fernández EM; García Fernández JM; Mellet CO Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]